Literature DB >> 1618236

Comparison of stress-only vs. stress/rest with technetium-99m methoxyisobutylisonitrile myocardial perfusion imaging.

D F Worsley1, A Y Fung, D B Coupland, C G Rexworthy, G P Sexsmith, B C Lentle.   

Abstract

Unlike conventional thallium-201 myocardial imaging, technetium-99m methoxyisobutylisonitrile (MIBI) requires separate stress and rest injections. We prospectively studied 148 consecutive patients referred for myocardial perfusion studies to determine the diagnostic value of rest images once normal exercise or dipyridamole tomographic images had been obtained. In patients referred with no history of previous myocardial infarction in whom the diagnosis of coronary artery disease was suspected, 45 of 109 (41%) patients had normal stress tomographic images. Obtaining rest images did not alter the final interpretation in any of these cases. From this we infer that in patients with normal images after exercise or dipyridamole administration and no past history of myocardial infarction, 99mTc-MIBI rest images are not required. This provides several advantages including increased speed of diagnosis, decreased patient radiation exposure, improved cost efficiency and decreased demand on tomographic camera time.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618236     DOI: 10.1007/bf00177372

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  13 in total

1.  A comparison of same day and separate day injection protocols for myocardial perfusion SPECT using 99Tcm-MIBI.

Authors:  D R Whalley; J J Murphy; M Frier; M L Wastie; R G Wilcox
Journal:  Nucl Med Commun       Date:  1991-02       Impact factor: 1.690

2.  Quantitative rotational tomography with 201Tl and 99mTc 2-methoxy-isobutyl-isonitrile. A direct comparison in normal individuals and patients with coronary artery disease.

Authors:  J K Kahn; I McGhie; M S Akers; M N Sills; T L Faber; P V Kulkarni; J T Willerson; J R Corbett
Journal:  Circulation       Date:  1989-06       Impact factor: 29.690

3.  Late reversibility of tomographic myocardial thallium-201 defects: an accurate marker of myocardial viability.

Authors:  H Kiat; D S Berman; J Maddahi; L De Yang; K Van Train; A Rozanski; J Friedman
Journal:  J Am Coll Cardiol       Date:  1988-12       Impact factor: 24.094

4.  Role of exercise thallium-201 myocardial perfusion scintigraphy in predicting prognosis in suspected coronary artery disease.

Authors:  J H Koss; S M Kobren; A M Grunwald; M M Bodenheimer
Journal:  Am J Cardiol       Date:  1987-03-01       Impact factor: 2.778

5.  Technetium-99m hexakis 2-methoxy-2-isobutyl isonitrile and thallium-201 extraction, washout, and retention at varying coronary flow rates in rabbit heart.

Authors:  R C Marshall; E M Leidholdt; D Y Zhang; C A Barnett
Journal:  Circulation       Date:  1990-09       Impact factor: 29.690

6.  99mTc-MIBI (RP-30) to define the extent of myocardial ischemia and evaluate ventricular function.

Authors:  M P Larock; R Cantineau; V Legrand; H Kulbertus; P Rigo
Journal:  Eur J Nucl Med       Date:  1990

7.  Myocardial kinetics of Tc-MIBI in canine myocardium after dipyridamole.

Authors:  D K Glover; R D Okada
Journal:  Circulation       Date:  1990-02       Impact factor: 29.690

8.  Dipyridamole-thallium scanning in patients undergoing vascular surgery. Optimizing preoperative evaluation of cardiac risk.

Authors:  K A Eagle; D E Singer; D C Brewster; R C Darling; A G Mulley; C A Boucher
Journal:  JAMA       Date:  1987-04-24       Impact factor: 56.272

9.  Kinetics of Tc-99m hexakis t-butyl isonitrile in normal and ischemic canine myocardium.

Authors:  S J Williams; D L Dragotakos; R D Okada
Journal:  Eur J Nucl Med       Date:  1989

10.  Exercise thallium-201 scintigraphy in men with nondiagnostic exercise electrocardiograms. Prognostic implications.

Authors:  A S Iskandrian; A H Hakki; S Kane-Marsch
Journal:  Arch Intern Med       Date:  1986-11
View more
  10 in total

1.  Role of the technologist in nuclear cardiology.

Authors:  A Mann; M P White
Journal:  J Nucl Cardiol       Date:  1998 Jul-Aug       Impact factor: 5.952

2.  A cost-effective sestamibi protocol in the managed health care era.

Authors:  E Milan; R Giubbini; G Gioia; A Terzi; A E Iskandrian
Journal:  J Nucl Cardiol       Date:  1997 Nov-Dec       Impact factor: 5.952

Review 3.  The maze of myocardial perfusion imaging protocols in 1994.

Authors:  F J Wackers
Journal:  J Nucl Cardiol       Date:  1994 Mar-Apr       Impact factor: 5.952

4.  Should imaging at stress always be followed by imaging at rest in Tc-99m MIBI SPECT? A proposal for a selective referral and imaging strategy.

Authors:  J M Schroeder-Tanka; M M Tiel-van Buul; E E van der Wall; W Roolker; K I Lie; E A van Royen
Journal:  Int J Card Imaging       Date:  1997-08

Review 5.  Stress-only SPECT myocardial perfusion imaging: a review.

Authors:  B M Pampana Gowd; Gary V Heller; Matthew W Parker
Journal:  J Nucl Cardiol       Date:  2014-07-09       Impact factor: 5.952

Review 6.  Myocardial viability: what do we need?

Authors:  H Schoeder; M Friedrich; H Topp
Journal:  Eur J Nucl Med       Date:  1993-09

7.  Adding attenuation corrected images in myocardial perfusion imaging reduces the need for a rest study.

Authors:  Elin Trägårdh; Sven Valind; Lars Edenbrandt
Journal:  BMC Med Imaging       Date:  2013-04-01       Impact factor: 1.930

8.  Stress-first single photon emission computed myocardial perfusion imaging.

Authors:  C I Aquino; M Scarano; F Squame; G Casaburi; S L Nori; L Pace
Journal:  Transl Med UniSa       Date:  2016-11-01

9.  Simplified approach to stress-first nuclear myocardial perfusion imaging: implementation of Choosing Wisely recommendations.

Authors:  David Winchester; Randy Jeffrey; David Wymer; Vicente Taasan; Anita Wokhlu
Journal:  BMJ Open Qual       Date:  2019-04-08

10.  Nuclear medicine technologists are able to accurately determine when a myocardial perfusion rest study is necessary.

Authors:  Elin Trägårdh; Liselott Johansson; Camilla Olofsson; Sven Valind; Lars Edenbrandt
Journal:  BMC Med Inform Decis Mak       Date:  2012-09-04       Impact factor: 2.796

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.